Assembly Biosciences, Inc. (ASMB)
Chart Events
Performance Outlook
| Previous Close | 4.1000 |
| Open | 4.1000 |
| Bid | 4.1100 x 1000 |
| Ask | 4.1200 x 1100 |
| Day's Range | 4.0100 - 4.1400 |
| 52 Week Range | 4.0100 - 27.8400 |
| Volume | 469,074 |
| Avg. Volume | 1,330,379 |
| Market Cap | 164.242M |
| Beta (5Y Monthly) | 0.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7540 |
| Earnings Date | Feb 25, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.40 |
Fair Value
Related Research
- Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
- Analyst Report: Gilead Sciences, Inc.
- GlobeNewswire
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 26,000 shares of the Company’s common stock with an exercise price of $5.05 per share, the closing price of Assembly Bio’s common stock on March 1, 2021. The stock options were granted as material inducements to the new employees to accept the Company’s offers of employment. The stock options have a ten-year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in approximately equal monthly installments. The stock options are, in all cases, subject to the new employees’ continued service with Assembly Bio through the applicable vesting dates and to acceleration upon the occurrence of certain events as set forth in the award agreements evidencing the stock options. None of the new employees are executive officers. The stock options were granted outside of Assembly Bio’s stockholder-approved equity incentive plans pursuant to Assembly Bio’s 2020 Inducement Award Plan. The stock option awards were approved by the Compensation Committee of Assembly Bio’s Board of Directors, which is comprised solely of independent directors, as a material inducement to entering into employment with Assembly Bio in accordance with Nasdaq Listing Rule 5635(c)(4), which requires this public announcement. About Assembly BiosciencesAssembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets. For more information, visit assemblybio.com. ContactsAssembly BioLauren GlaserSenior Vice President, Investor Relations and Corporate Affairs(415) 521-3828lglaser@assemblybio.com
- Motley Fool
Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation fourth-quarter and year-end 2020 financial results and corporate update conference call. Good morning, and thank you for joining the Arbutus Biopharma fourth-quarter 2020 conference call and webcast. On the call today are Bill Collier, president and chief executive officer; Dr. Gaston Picchio, chief development officer; Dr. Michael Sofia, chief scientific officer; and Dave Hastings, chief financial officer.
- Benzinga
Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection
Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for chronic HBV infection. The companies announced a clinical collaboration agreement in August last year. The 60-subject trial will evaluate the safety, pharmacokinetics, and antiviral activity of the triplet combination compared to the double combinations of VBR plus NrtI and AB-729 plus NrtI. AB-729 is an RNA interference therapeutic targeted to hepatocytes. Vebicorvir is a capsid inhibitor. Earlier today, Assembly Biosciences announced that it would not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as chronic suppressive therapy. Price Action: ASMB shares are trading 5.9% lower at $5.2, while ABUS is down 0.8% at $3.8 in market trading hours on the last check Friday. See more from BenzingaClick here for options trades from BenzingaAssembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
